SOUTH SAN FRANCISCO — Freenome, a biotechnology company pioneering the field of multiomics for early disease detection, announced today that it will unveil new clinical validation data for its next-generation colorectal cancer (CRC) screening test. The findings, selected for a prestigious late-breaking oral presentation at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting on October 14, signal a significant advancement in the detection of precancerous lesions.
The company’s latest data demonstrates a substantial improvement in clinical performance, specifically regarding the detection of advanced precancerous lesions. According to the abstract, the test achieved a sensitivity of 41.9% for lesions characterized by high-grade dysplasia. This represents a marked increase over the 30.5% sensitivity reported in earlier iterations of the study, suggesting that Freenome’s multiomics approach is becoming increasingly adept at identifying high-risk growths before they progress to invasive cancer.
Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide, yet it is highly preventable when detected at the precancerous stage. The current standard of care—colonoscopy—remains the gold standard for screening, but patient compliance remains a global challenge due to the invasive nature and preparation requirements of the procedure. Freenome’s cell-free blood test is designed to improve screening accessibility and compliance by combining genomic, epigenomic, and proteomic data with machine learning to identify signals associated with colorectal malignancy.
“We are encouraged by these results, which highlight the power of our multiomics platform to identify high-grade dysplasia with greater precision,” said a representative from Freenome. “Improving the sensitivity for advanced precancerous lesions is a critical step in reducing the incidence of colorectal cancer. By catching these lesions earlier, we provide clinicians with a more reliable, non-invasive tool to intervene before cancer develops.”
The ACG 2026 presentation will detail the analytical and clinical validation methodologies used to reach these updated metrics. The increase in sensitivity, from 30.5% to 41.9%, is being viewed by industry analysts as a vital performance milestone that could position Freenome as a significant player in the competitive landscape of liquid biopsy diagnostics.
As the medical community gathers in the coming days, the presentation is expected to draw significant attention from gastroenterologists, oncologists, and health policy experts. If these data hold up under peer review and are reflected in future large-scale, prospective screening populations, the Freenome test could become a cornerstone of routine CRC screening programs.
Following the oral presentation at the ACG conference, Freenome plans to continue its clinical development efforts, moving toward regulatory submissions that could eventually bring this next-generation test to clinical practice. The data underscores the potential for multiomics to shift the focus of cancer care from reactive treatment to proactive, precision-based prevention.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
